These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18289085)

  • 1. Carbohydrate-based drugs in the treatment of epilepsy, depression and other affective disorders.
    Talisman IJ; Marzabadi CH
    Curr Top Med Chem; 2008; 8(2):159-70. PubMed ID: 18289085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of carbohydrates in approved small molecule drugs: A review.
    Jiang H; Qin X; Wang Q; Xu Q; Wang J; Wu Y; Chen W; Wang C; Zhang T; Xing D; Zhang R
    Eur J Med Chem; 2021 Nov; 223():113633. PubMed ID: 34171659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
    Gray NA; Zhou R; Du J; Moore GJ; Manji HK
    J Clin Psychiatry; 2003; 64 Suppl 5():3-17. PubMed ID: 12720479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the vasopressin system for the treatment of CNS diseases.
    Ryckmans T
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrug approaches to reduce hyperexcitation in the CNS.
    Vytla D; Combs-Bachmann RE; Hussey AM; McCarron ST; McCarthy DS; Chambers JJ
    Adv Drug Deliv Rev; 2012 May; 64(7):666-85. PubMed ID: 22138074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of coumarins towards central nervous system disorders.
    Skalicka-Woźniak K; Orhan IE; Cordell GA; Nabavi SM; Budzyńska B
    Pharmacol Res; 2016 Jan; 103():188-203. PubMed ID: 26657416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidence.
    Banister SD; Kassiou M
    Curr Pharm Des; 2012; 18(7):884-901. PubMed ID: 22288410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan G protein-coupled receptors: The role in CNS disorders.
    Alavi MS; Shamsizadeh A; Azhdari-Zarmehri H; Roohbakhsh A
    Biomed Pharmacother; 2018 Feb; 98():222-232. PubMed ID: 29268243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.
    Gregory KJ; Noetzel MJ; Niswender CM
    Prog Mol Biol Transl Sci; 2013; 115():61-121. PubMed ID: 23415092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ; Thorne RG
    Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms.
    Chang KD; Dienes K; Blasey C; Adleman N; Ketter T; Steiner H
    J Clin Psychiatry; 2003 Aug; 64(8):936-42. PubMed ID: 12927009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future therapeutic targets in mood disorders: the glucocorticoid receptor.
    McQuade R; Young AH
    Br J Psychiatry; 2000 Nov; 177():390-5. PubMed ID: 11059990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxic effects of drugs on the central nervous system].
    Poser S; Poser W
    Nervenarzt; 1983 Dec; 54(12):615-23. PubMed ID: 6664389
    [No Abstract]   [Full Text] [Related]  

  • 15. [Mood disorders, psychopharmacology and thyroid hormones].
    Danilo Q; Gloger S; Valdivieso S; Ivelic J; Fardella C
    Rev Med Chil; 2004 Nov; 132(11):1413-24. PubMed ID: 15693206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuro-immune axis: prospect for novel treatments for mental disorders.
    Kraneveld AD; de Theije CG; van Heesch F; Borre Y; de Kivit S; Olivier B; Korte M; Garssen J
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):128-36. PubMed ID: 24118847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mice selected for high versus low stress reactivity: a new animal model for affective disorders.
    Touma C; Bunck M; Glasl L; Nussbaumer M; Palme R; Stein H; Wolferstätter M; Zeh R; Zimbelmann M; Holsboer F; Landgraf R
    Psychoneuroendocrinology; 2008 Jul; 33(6):839-62. PubMed ID: 18502051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function.
    Nikisch G
    Neuro Endocrinol Lett; 2009 Mar; 30(1):11-6. PubMed ID: 19300389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In this issue of Recent Patents on CNS Drug Discovery, focus is laid upon the potential development of new therapeutic drugs for neurological and affective disorders through targeting the endocannabinoid system. Introduction.
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):1-2. PubMed ID: 22384488
    [No Abstract]   [Full Text] [Related]  

  • 20. Delivery of therapeutics to the central nervous system.
    Chambers JJ
    Adv Drug Deliv Rev; 2012 May; 64(7):589. PubMed ID: 22388004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.